Sonnet BioTherapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Deficit) (Details Narrative)

Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)								1 Months Ended	3 Months Ended					9 Months Ended
	Jun. 21, 2024	Jun. 19, 2024	May 02, 2024	Oct. 26, 2023	Jun. 30, 2023	Feb. 10, 2023	Aug. 15, 2022	Oct. 31, 2023	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2024	Jun. 30, 2023	Dec. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares, value									$ 62,019	$ 3,916,943	$ 1,945,677	$ 14,515,968	$ 4,452,012
Gross proceeds from sale agreement						$ 15,000,000.0
Financing costs incurred														$ 157,500
Proceeds from sale of common stock						$ 13,600,000								$ 3,899,157	21,024,070
Warrant, shares									10,128,103					10,128,103
Proceeds from warrant exercises														$ 3,002,968	$ 849
Underwriter Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued						44,190
Exercise price						$ 29.70
Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued					166,363
Warrant issued					227,272						227,272				227,272
Sales price, per share					$ 9.90						$ 9.90				$ 9.90
Warrants exercise price reduced														$ 1.55
Gross proceeds from private placement					$ 2,300,000
Net proceeds from issuance of private placement					$ 1,900,000
October Offering [Member] \| Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from sale of common stock				$ 3,900,000
Warrant issued				85,312
Exercise price				$ 2.00
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares, value									$ 4	$ 131	$ 17	$ 56	$ 11
Number of shares issued									37,654	1,306,250	166,364	557,083	109,841
Sales price, per share						$ 23.76
Net share settlement of warrants, shares									739,950	14,362	508,834	10,521	137
Common Stock [Member] \| Investors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued						530,222
Warrant issued						1,262,618
Common Stock [Member] \| October Offering [Member] \| Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of stock, shares				1,306,250
Exercise price				$ 0.0001
Prefunded Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sales price, per share						$ 23.7578
Exercisable price per share						$ 0.0022
Prefunded Warrant [Member] \| Investors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued						101,090
Prefunded Warrant [Member] \| October Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued									797,500					797,500
Exercise price									$ 0.0001					$ 0.0001
Warrant, shares									1,500,000					1,500,000
Prefunded Warrant [Member] \| October Offering [Member] \| Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued				1,537,500
Sales price, per share				$ 1.5999
Common Warrant [Member] \| October Offering [Member] \| Underwriters [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued				5,687,500
Sales price, per share				$ 1.60
Exercise price				$ 1.60
Warrants exercise price reduced														$ 1.20
Common Stock Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued														754,312	519,492
Warrant, shares									1,500,000					1,500,000
Net share settlement of warrants, shares														768,724	1,014,872
Number of warrant exercised														2,863,500	137,998
Proceeds from warrant exercises														$ 3,000,000.0
Number of warrant expired															332
Common Stock Warrants [Member] \| Holder [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Forfeited warrants, shares														34,458
Purchase And Registration Rights Agreement [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares, value			$ 25,000,000.0
Number of shares issued			622,168
Sale of stock, percentage			19.99%
Volume weighted average price discount percentage			4.00%
Sale of stock, shares									37,654					37,654
Gross proceeds from sale agreement									$ 100,000					$ 100,000
Purchase Agreement [Member] \| Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Financing costs incurred									$ 400,000					$ 400,000
2022 Sales Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares, value							$ 7,800,000
2022 Sales Agreement [Member] \| Underwriter Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued																6,818
2022 Sales Agreement [Member] \| BTIG, LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares, value							$ 25,000,000.0
Sale of stock, shares															136,702
Gross proceeds from sale agreement															$ 5,700,000
Proceeds from sale of common stock															$ 5,500,000
2022 Sales Agreement [Member] \| Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price					$ 0.0022						$ 0.0022				$ 0.0022
2022 Sales Agreement [Member] \| Prefunded Warrant [Member] \| Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued					60,909						60,909				60,909
2022 Sales Agreement [Member] \| Common Warrant [Member] \| Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price																$ 14.8478
Inducement Offer Letter Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price								$ 1.60
Warrants exercise price reduced								$ 1.20
Aggregate number of shares issued								2,828,500
Gross proceeds from sale agreement	$ 3,400,000
Net proceeds from sale agreement	$ 2,900,000
Warrant, shares									1,500,000					1,500,000
Inducement Offer Letter Agreements [Member] \| Placement Agent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant issued		113,140
Exercise price		$ 1.86
Expire year		5 years
Inducement Offer Letter Agreements [Member] \| New Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, shares		5,625,000
Inducement Offer Letter Agreements [Member] \| Existing Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price								$ 1.60
Warrants exercise price reduced		$ 1.20
Warrant, shares		2,840,000
Inducement Offer Letter Agreements [Member] \| Existing Warrant Issued In June 2023 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, shares					227,272						227,272				227,272
Inducement Offer Letter Agreements [Member] \| Existing Warrant Issued In June 2023 [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price					$ 14.8478						$ 14.8478				$ 14.8478
Warrant expiration date					Jun. 21, 2029						Jun. 21, 2029				Jun. 21, 2029
Inducement Offer Letter Agreements [Member] \| Existing Warrant Issued In June 2023 [Member] \| Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price									$ 1.55					$ 1.55
Warrant expiration date					Dec. 30, 2026						Dec. 30, 2026				Dec. 30, 2026
Inducement Offer Letter Agreements [Member] \| New Common Stock Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price		$ 1.55
Expire year		5 years